Subthalamic CaMKIIα-expressing neurons facilitate recovery from propofol anesthesia via the STN–ventral pallidum pathway Authors: Shangqin Bai, Yiqiu Chen, Yu Li, Xiao Liu, Yanyan Ba, Qingbin Chen, Xiangqing Song, Haisheng Zhang, Xiaochun Lai, Lin Xue, Pei Sun, He Zhu, Jingyu Xiao, Wen Li, Xuejun Wang Published: 2026 ABSTRACT Propofol is extensively used in clinical anesthesia, yet its mechanisms of action remain incompletely understood. CaMKIIα-expressing neurons in the subthalamic nucleus (STN) have been associated with arousal-related pain perception and impulse regulation, but their role in propofol anesthesia remains unclear. In this study, c-Fos immunohistochemistry, live calcium-signal recording by fiber photometry, electroencephalography (EEG), and electromyography (EMG) were employed to assess the activity of STN CaMKIIα-expressing neurons during propofol anesthesia. It was observed that the activity of STN CaMKIIα-expressing neurons was markedly reduced under propofol anesthesia. Both optogenetic and chemogenetic activation of this population promoted cortical arousal and shortened recovery time without affecting anesthetic induction. Through anterograde and retrograde tracing approaches, a direct projection from the STN to the ventral pallidum (VP) was identified. Optogenetic stimulation of STN CaMKIIα-expressing axon terminals within the VP modified EEG spectral power during maintenance and emergence and enhanced emergence from propofol anesthesia. Collectively, these findings indicate that STN CaMKIIα-expressing neurons play an important role in promoting behavioral emergence from propofol anesthesia, at least partially through the STN–VP circuit. This study provides circuit-level evidence that improves mechanistic insight into emergence from general anesthesia and identifies the STN-VP pathway as a potential target for modulating anesthetic recovery.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10565-026-10195-y. Introduction General anesthesia induces a reversible state of unresponsiveness that is essential for successful surgical procedures and patient safety. Propofol is the most commonly administered intravenous anesthetic owing to its rapid onset, efficient metabolism, predictable recovery, and relatively favorable side-effect profile (Sahinovic et al. 2018). Despite its widespread clinical application, the neural mechanisms through which propofol alters consciousness remain insufficiently understood. Growing convergence between anesthesiology and sleep–wake research suggests that anesthetics can generate EEG patterns similar to natural sleep (Brown et al. 2010; Guang et al. 2025; Lydic and Baghdoyan. 2005; Sharma et al. 2018; Wang et al. 2020) and induce unconsciousness by engaging endogenous arousal networks, including the parabrachial nucleus (PBN) (Li et al. 2022; Wang et al. 2019), locus coeruleus (LC) (Hu et al. 2012; Vazey and Aston-Jones 2014), ventral tegmental area (VTA) (Solt et al. 2014; Taylor et al. 2016), and bed nucleus of the stria terminalis (BNST) (Li et al. 2024). Nevertheless, whether additional arousal-promoting regions contribute to anesthetic-induced alterations in consciousness remains uncertain. The basal ganglia (BG), an evolutionarily conserved system involved in emotion, cognition, and motor regulation, also contributes to sleep–wake control (Liu et al. 2020; Luo et al. 2018b; Pierce and Péron 2020). The subthalamic nucleus (STN), a core component of the BG composed primarily of glutamatergic neurons (Wallén-Mackenzie et al. 2020), regulates several arousal-related behaviors, including nociception (Jia et al. 2022; Luan et al. 2020), learning and memory (Coulthard et al. 2012), and stress responses (Jia et al. 2023). Notably, medial STN (mSTN) corticotropin-releasing hormone (CRH) neurons drive rapid eye movement (REM)–associated arousal and defensive behaviors (Tseng et al. 2022), and STN deep brain stimulation (DBS) improves sleep architecture in patients with Parkinson’s disease by suppressing abnormal STN activity (Jost et al. 2021). Taken together, these findings underscore an important role of the STN in arousal regulation, yet its involvement in general anesthesia remains largely unexplored. Accumulating evidence suggests that the STN is involved in the regulation of general anesthesia. A clinical investigation reported that propofol-induced unconsciousness enhances low-frequency STN oscillations and decreases high-frequency activity, while noxious stimuli such as tracheal intubation reverse this pattern with prominent β-band activation (Huang et al. 2020). Consistent with these findings, Aeyal Raz et al. demonstrated that propofol decreases STN neuronal firing rates (Raz et al. 2010). Similarly, a clinically relevant dose of dexmedetomidine strongly suppresses STN activity and leads to sustained reductions in firing (Amlong et al. 2022). Together, these observations suggest that propofol modulates STN function, but whether STN CaMKIIα-expressing neurons are involved in propofol-related brain-state transitions, particularly during emergence, remains unclear. In the present study, activity changes in STN CaMKIIα-expressing neurons across different stages of propofol anesthesia were initially measured using c-Fos immunohistochemistry and in vivo fiber photometry. Subsequently, optogenetic and chemogenetic manipulations combined with EEG–EMG recordings and behavioral assays were employed to evaluate their causal roles during anesthesia and emergence. Anterograde and retrograde tracing techniques identified synaptic projections between STN CaMKIIα-expressing neurons and the ventral pallidum (VP). Pathway-specific optogenetic stimulation was further used to determine whether the STN–VP projection influences propofol anesthesia. The results demonstrate that STN CaMKIIα-expressing neurons serve as an important arousal-related node that facilitates emergence from propofol anesthesia, at least in part via downstream VP circuits. These findings shed new light on the circuit mechanisms involved in behavioral emergence from general anesthesia. Methods Animals Adult male C57BL/6 mice (6–8 weeks, 22–28 g) were utilized in the experiments. Only male mice were included to reduce potential confounding effects of sex-related hormonal variability. Mice were maintained in groups of no more than five per cage under standard housing conditions, with free access to food and water, a controlled ambient temperature of 24 ± 1 °C, relative humidity of 50 ± 5%, and a 12 h light/dark cycle (lights on from 08:00 to 20:00). All experimental procedures were approved by the Animal Experiment Ethics Committee of Qinghai Red Cross Hospital and complied with institutional animal-care guidelines (KY-2024–47). Viral injections and surgical procedures Mice were anesthetized by intraperitoneal administration of sodium pentobarbital (50 mg/kg) (Li et al. 2025) and then secured in a stereotaxic frame. After scalp disinfection with povidone-iodine and local administration of 2% lidocaine, a midline incision was created along the sagittal suture to expose the skull and locate bregma and lambda. A 0.5 × 0.5 mm craniotomy was then performed above the target coordinates for viral delivery and subsequent optical fiber implantation. Body temperature was maintained during surgical procedures. Because the STN is primarily a glutamatergic nucleus and the CaMKIIα promoter preferentially drives expression in excitatory neurons, CaMKIIα-driven viral constructs were used to target a mainly excitatory neuronal population within the STN (Gradinaru et al. 2009; Ji et al. 2023). However, as CaMKIIα does not provide definitive confirmation of glutamatergic identity in this region, the manipulated population in the present study is more accurately defined as STN CaMKIIα-expressing neurons. Accordingly, all viral vectors used for fiber photometry, chemogenetic, optogenetic, and anterograde tracing experiments were placed under the control of the CaMKIIα promoter. For fiber photometry experiments, 150–200 nL of AAV2/9-CaMKIIα-GCaMP6m (PT-0111, 2.0 × 1012 vg/mL; BrainVTA Technology Co., Wuhan, China) was unilaterally injected into the STN (anteroposterior [AP] –1.9 mm, mediolateral [ML] ±1.5 mm, dorsoventral [DV] –4.6 mm from the skull surface) using a microinjection pump. For optogenetic experiments, AAV2/9-CaMKIIα-ChR2-mCherry (S0166-9), AAV2/9-CaMKIIα-eNpHR3.0-mCherry (S0464-9), or AAV2/9-CaMKIIα-mCherry (S0242-9) (1.2 × 1013 vg/mL; Taitool Bioscience Co.; 150–200 nL per site) was bilaterally delivered into the STN. For chemogenetic experiments, AAV2/9-CaMKIIα-hM3Dq-mCherry (S0140-9), AAV2/9-CaMKIIα-hM4Di-mCherry (S0494-9), or AAV2/9-CaMKIIα-mCherry (S0242-9) (1.2 × 1013 vg/mL; Taitool Bioscience Co.; 150–200 nL per site) was injected bilaterally into the STN. For anterograde tracing of STN efferents, 100 nL of a viral mixture containing AAV2/9-DIO-EGFP (PT-1103, 4.2 × 1012 vg/mL; BrainVTA Technology Co., Wuhan, China) and AAV2/9-CaMKIIα-Cre (PT-0220, 1.2 × 1012 vg/mL; BrainVTA Technology Co., Wuhan, China) was injected into the right STN. To selectively retrogradely label VP-projecting CaMKIIα-expressing neurons in the STN, a two-step viral approach was applied. First, AAV2/2-Retro-DIO-EGFP (S0277, 2.5 × 1013 vg/mL; Obio Biotechnology Co., Ltd., Shanghai, China; 100 nL) was stereotaxically delivered to the right VP ([AP] 0.5 mm, [ML] 1.5 mm, [DV] –5.1 mm from the skull surface). Subsequently, AAV2/9-CaMKIIα-Cre (S0906-9, 1.2 × 1013 vg/mL; Taitool Bioscience Co.; 100 nL) was delivered into the ipsilateral right STN. This strategy restricts EGFP expression to VP-projecting neurons within the STN that express CaMKIIα. After surgery, the mice were kept on a warming pad until they regained consciousness and were subsequently returned to their home cages. Postoperative analgesia was administered with meloxicam (5 mg/kg, s.c.) once daily for 2 days. After 3–4 weeks, a second surgical procedure was conducted to implant optical fibers (100-μm core diameter, numerical aperture 0.5; Inper) above the viral injection sites (STN: AP –1.9 mm, ML ±1.5 mm, DV –4.5 mm; VP: AP 0.5 mm, ML ±1.5 mm, DV –5.0 mm from the skull surface). Fiber photometry recording Fiber photometry signals were acquired with the Inper fiber photometry system (Inper, China) during simultaneous EEG and EMG acquisition with synchronized recording setups. Calcium-dependent fluorescence was measured using alternating 470-nm and 410-nm excitation, where the 470-nm channel served as the signal channel and the 410-nm channel functioned as the control/reference channel. Prior to formal recording, signals were previewed to confirm baseline stability. Data were analyzed using Inper Plot (v1.9.0), in which the 470-nm trace was defined as Signal and the 410-nm trace as Control. Preprocessing included baseline correction and control-based subtraction to minimize motion-related artifacts, photobleaching, and slow nonspecific fluctuations. The photometric signal was then calculated as ΔF/F = (F-F0)/F0 using the “Relative with Marker” option, and signals were aligned to loss of righting reflex (LORR) and return of the righting reflex (RORR) for event-based normalization and analysis. To limit the influence of long-term baseline drift during propofol infusion, induction- and recovery-related signal changes were quantified using event-aligned windows around LORR and RORR rather than relying solely on the full-session fluorescence trace. The hypnotic effect of propofol was assessed using LORR. During propofol infusion, mice were gently turned to a supine position every 15 s, and the ability to regain a normal prone posture was monitored. LORR was considered to occur when the mouse failed to right itself onto all four paws for more than 30 s; the onset of this period was defined as the LORR time point. RORR was defined as the time at which the mouse spontaneously resumed a normal prone posture after discontinuation of propofol infusion (Wang et al. 2023). EEG-EMG data acquisition and analysis For EEG recordings, three electrodes were inserted through small burr holes over the cerebral cortex, with two electrodes placed over the frontal cortex and one over the parietal cortex serving as a reference. For EMG recordings, two silver-plated wire electrodes were inserted into the nuchal muscles. The electrode assembly was secured to the skull using dental cement. EEG–EMG recordings were conducted 7 days after implantation using an amplifier system (Chengdu Instrument Factory, Chengdu, China). Before analysis, EEG and EMG signals were band-pass filtered to eliminate low- and high-frequency noise components (EEG: 0.1–30 Hz; EMG: 10–70 Hz) and exported to MATLAB R2023b (MathWorks, Natick, MA, USA) for further processing. EEG power spectra were computed using Fast Fourier Transform (FFT) with 4-s windows and 50% overlap across the 0.1–30 Hz frequency range. Normalized power spectral density (PSD) was calculated to determine relative power in the delta (0.1–4 Hz), theta (4–8 Hz), alpha (8–15 Hz), and beta (15–30 Hz) frequency bands (Wang et al. 2023). Anesthesia behavioral experiments Stable general anesthesia was induced and maintained using propofol via continuous tail-vein infusion during both the induction and maintenance stages. The hypnotic effects of propofol were assessed using LORR and RORR as behavioral endpoints, as described above. To evaluate whether subthalamic CaMKIIα-expressing neurons contribute to propofol-induced loss and behavioral emergence, a two-phase chemogenetic manipulation strategy was applied. Clozapine N-oxide (CNO; 3 mg/kg) was prepared in dimethyl sulfoxide (DMSO) and diluted with normal saline to achieve a final DMSO concentration of 2.64%. Mice received intraperitoneal injections of CNO (3 mg/kg) or vehicle (2.64% DMSO in saline) 30 min before anesthesia induction (Zhou et al. 2024). Propofol was subsequently infused through the tail vein at 10 mg/kg/min, and induction time was defined as the duration from infusion onset to LORR (Wang et al. 2023). During the maintenance and emergence stages, CNO or saline was administered intraperitoneally 30 min after establishing stable anesthesia (propofol, 2 mg/kg/min). Propofol infusion was terminated 60 min later, and emergence time was defined as the interval from infusion cessation to RORR. For optogenetic experiments, mice with verified viral expression were connected to an integrated system for EEG/EMG recording and optical stimulation. After a 30-min habituation period and a subsequent 30-min baseline recording in the awake state, propofol was infused via the tail vein at 10 mg/kg/min. Once LORR was achieved, the infusion rate was reduced to 2 mg/kg/min to maintain a stable anesthetic state. Thirty minutes after the start of the maintenance phase, light stimulation was delivered through the implanted optical fibers using an optogenetic stimulator and optical commutator (Inper, China). For activation experiments, the same blue-light stimulation parameters were used for both STN somata and STN–VP terminals (465 nm, 20 Hz, 10 ms pulse width, 180 s, 5 mW at the fiber tip). For inhibition experiments, the same yellow-light stimulation parameters were applied to both STN somata and STN–VP terminals (589 nm, 1-s pulses, 180 s, 5 mW at the fiber tip); in the stimulation software, this protocol was configured as 1 Hz with a pulse width of 1 s, which functionally approximates continuous illumination (Jia et al. 2022). Propofol infusion was stopped 60 min after the beginning of the maintenance stage, followed by a final round of optical stimulation during the emergence phase. Arousal scoring During continuous propofol anesthesia, arousal responses evoked by acute photostimulation of STN CaMKIIα-expressing neurons were quantified from video recordings using a previously established scoring method. Five behavioral components were evaluated (Taylor et al. 2016): respiratory rate (increased vs. unchanged), limb movement, neck lifting, righting, and locomotion, and the sum of all components produced a composite arousal score with a maximum of 10 points. Specifically, respiratory rate was assigned 2 points for increased respiration or 0 points for unchanged respiration. Limb movement was scored as 2 points for pronounced limb shaking, 1 point for mild shaking, and 0 points for no movement. Neck activity was scored as 2 points for continuous head lifting lasting ≥ 5 s and 0 points otherwise. Postural correction (righting) was scored as 2 points if present and 0 points if absent. Locomotion was scored as 2 points for walking with the abdomen off the ground after postural correction, 1 point for walking with the abdomen elevated, and 0 points for no walking. Arousal responses were quantified using predefined behavioral criteria and a fixed composite scoring system to minimize subjectivity in behavioral evaluation. Immunocytochemistry Mice underwent transcardial perfusion first with phosphate-buffered saline (PBS) and then with 4% paraformaldehyde (PFA; Sigma). The brains were removed and post-fixed in the same fixative for 12 h, followed by sequential cryoprotection in 20% and 30% sucrose, and coronally sectioned at 40 μm using a cryostat (FS800A, RWD, China). Sections were rinsed in PBS, permeabilized with 0.7% Triton X-100 for 1 h, and then incubated overnight at 4 °C with rabbit anti-Fos antibody (1:200, Abcam, ab190289). After additional PBS washes, the sections were treated with Alexa Fluor 488 donkey anti-rabbit secondary antibody (1:200, Invitrogen, A21206) for 2 h at room temperature, counterstained with DAPI (1:1000, Proteintech, CM07245), mounted, and imaged using a confocal microscope (TE2000-E, Nikon). For quantification, anatomically matched STN sections were selected from each mouse and analyzed in ImageJ (NIH, USA) using identical imaging settings within each experiment. The STN region of interest was defined based on the mouse brain atlas together with DAPI and viral fluorescence landmarks. For state-dependent c-Fos analysis, c-Fos-positive nuclei within the bilateral STN were counted and averaged across matched sections to generate a single value per mouse. For chemogenetic c-Fos experiments, the percentage of c-Fos-positive virus-labeled neurons was calculated as the number of c-Fos/mCherry double-labeled cells divided by the total number of mCherry-positive cells within the STN. Only mice with correct viral expression and accurate target localization were included in the final analysis. Statistical analysis Statistical analysis and data visualization were performed using GraphPad Prism 10 (GraphPad Software, USA) and MATLAB R2023b (MathWorks, Natick, MA, USA). Data normality was assessed with the Shapiro–Wilk test. Paired Student’s t-tests were used for within-animal comparisons in fiber photometry experiments. One-way ANOVA followed by Dunnett’s test was used for c-Fos comparisons among awake, anesthetized, and recovery groups, with the anesthetized group as the reference. Unpaired Student’s t-tests were used for chemogenetic c-Fos data. Optogenetic EEG data were analyzed by one-way repeated-measures ANOVA followed by Bonferroni’s post hoc test. LORR and RORR latencies among groups were compared using one-way ANOVA with Bonferroni’s correction. For non-normally distributed data, the Wilcoxon signed-rank test or Mann–Whitney U test was applied as appropriate. Statistical details are provided in the corresponding figure legends. Data are presented as mean ± SEM, and P < 0.05 was considered statistically significant. Data source and quality control This study did not involve any publicly available dataset. All analyzed data were obtained from original in vivo and histological experiments conducted by the authors. Accordingly, no public link or accession number is available. Only datasets meeting predefined quality criteria, including accurate viral targeting, valid signal recording, and complete behavioral or histological data, were included in the final analysis. Sample sizes are indicated in the corresponding figure legends. Results Population activities of STN CaMKIIα-expressing neurons are suppressed by propofol anesthesia C-Fos, a member of the immediate early gene (IEG) family, is commonly used as a marker of neuronal activation (Vendrell et al. 1998) and is widely applied to evaluate the relationship between neural activity in specific brain regions or neuronal populations and anesthesia-related behavioral states. C-Fos expression was first examined under a high-arousal awake condition, during propofol anesthesia, and after recovery from propofol anesthesia, and it was found that propofol anesthesia markedly reduced c-Fos expression, which increased again after recovery (Fig. S1A–C; high-arousal awake condition vs. anesthesia: 48.75 ± 4.99 vs. 8.25 ± 2.63, P < 0.001; anesthesia vs. recovery: 8.25 ± 2.63 vs. 29.75 ± 5.56, P = 0.0004). To further characterize the in vivo activity dynamics of STN CaMKIIα-expressing neurons during propofol anesthesia, AAV2/9-CaMKIIα-GCaMP6m was injected into the STN of C57BL/6 mice. Three weeks later, an optical fiber was implanted above the STN, and EEG–EMG electrodes were simultaneously placed on the cortical surface and neck muscles (Fig. 1A). Post hoc histological analysis verified robust expression of the Ca2+ indicator GCaMP6m and accurate placement of the fiber tip within the STN (Fig. 1B). Data acquisition was performed after a postoperative recovery period of no less than 7 days. Fluorescence signals from GCaMP6m-labeled STN CaMKIIα neurons were recorded via fiber photometry combined with EEG–EMG monitoring during the entire propofol anesthesia process (Fig. 1C). Representative traces indicated that fluorescence intensity rapidly decreased after propofol administration, gradually increased after infusion termination, and returned to levels comparable to the pre-propofol baseline as the drug was cleared (Fig. 1C). Quantitative analysis showed that, relative to baseline, the population activity of STN CaMKIIα-expressing neurons was significantly reduced during exposure to propofol at 10 mg/kg/min (Fig. 1D–G; Pre vs. Post: 0.61 ± 0.30 vs. –0.57 ± 0.18, P = 0.0164). After discontinuation of propofol, Ca2+ signal intensity increased toward baseline levels (Fig. 1H–K; Pre vs. Post: -12.05 ± 7.13 vs. -4.28 ± 5.48, P = 0.0284). Overall, these findings indicate that propofol anesthesia suppresses the population activity of STN CaMKIIα-expressing neurons.Fig. 1Propofol anesthesia markedly suppresses calcium signals in STN CaMKIIα-expressing neurons. A Schematic showing injection of AAV-CaMKIIα-GCaMP6m into the STN of C57BL/6 mice. B Confocal image displaying viral expression (green) and fiber tip localization within the STN, with DAPI (blue) used as a nuclear counterstain. C Experimental timeline and representative recording including EEG power spectrum, raw EEG–EMG traces, and Ca2+ signals. Freq., frequency. D Representative Ca2+ fluorescence trace from mice expressing GCaMP6m in STN CaMKIIα-expressing neurons during propofol induction. E, F Mean Ca2+ signals (E) and heatmaps of individual trials (F) aligned to LORR. G Quantification of Ca2+ activity before and after LORR. H Representative Ca2+ fluorescence trace during recovery from propofol. I, J Mean Ca2+ signals (I) and heatmaps of individual trials (J) aligned to RORR. K Quantification of Ca.2+ activity before and after RORR. n = 8 mice. Data are expressed as mean ± SEM. Statistical analysis was performed using paired Student’s t-test (G, K). *P < 0.05 Propofol anesthesia markedly suppresses calcium signals in STN CaMKIIα-expressing neurons. A Schematic showing injection of AAV-CaMKIIα-GCaMP6m into the STN of C57BL/6 mice. B Confocal image displaying viral expression (green) and fiber tip localization within the STN, with DAPI (blue) used as a nuclear counterstain. C Experimental timeline and representative recording including EEG power spectrum, raw EEG–EMG traces, and Ca2+ signals. Freq., frequency. D Representative Ca2+ fluorescence trace from mice expressing GCaMP6m in STN CaMKIIα-expressing neurons during propofol induction. E, F Mean Ca2+ signals (E) and heatmaps of individual trials (F) aligned to LORR. G Quantification of Ca2+ activity before and after LORR. H Representative Ca2+ fluorescence trace during recovery from propofol. I, J Mean Ca2+ signals (I) and heatmaps of individual trials (J) aligned to RORR. K Quantification of Ca.2+ activity before and after RORR. n = 8 mice. Data are expressed as mean ± SEM. Statistical analysis was performed using paired Student’s t-test (G, K). *P < 0.05 Photostimulation of STN CaMKIIα-expressing neurons promotes behavioral emergence and cortical activation during propofol anesthesia and emergence The next step was to determine whether activation of STN CaMKIIα-expressing neurons could promote arousal during propofol anesthesia. AAV-CaMKIIα-ChR2-mCherry or control AAV-CaMKIIα-mCherry was bilaterally injected into the STN of C57BL/6 mice (Fig. 2A). Three weeks after injection, EEG–EMG electrodes and optical fibers were implanted (Fig. 2B, left), and histology confirmed strong ChR2-mCherry expression in STN CaMKIIα-expressing neurons (Fig. 2B, right). Optical stimulation was delivered at two time points: 30 min into the maintenance phase of propofol anesthesia and immediately after propofol withdrawal (Fig. 2C).Fig. 2Optogenetic activation of STN CaMKIIα-expressing neurons induces EEG and behavioral arousal during propofol anesthesia. A Diagram of viral delivery. C57BL/6 mice received bilateral injections of AAV-CaMKIIα-ChR2-mCherry or control AAV-CaMKIIα-mCherry into the STN. B Left, four weeks later, optical fibers and EEG/EMG electrodes were implanted. Right, representative histological image confirming ChR2-mCherry expression and fiber track placement in the STN. Scale bar, 100 μm. C Experimental protocol for propofol anesthesia. Following LORR, propofol was maintained at 2 mg/kg/min. Red dashed boxes indicate photostimulation (465 nm, 20 Hz, 10 ms pulse width, 180 s, 5 mW at the fiber tip) during the maintenance phase, and green dashed boxes indicate identical stimulation applied shortly before emergence. D Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after photostimulation during maintenance in the ChR2 group. E Group-averaged EEG power spectra (0–30 Hz) in the ChR2 group across pre-, stimulation-, and post-stimulation periods. F Quantification of relative EEG band power (delta, theta, alpha, beta) in the ChR2 group during maintenance. G Representative EEG spectrogram and EEG/EMG traces in the mCherry control group. H Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during maintenance. I Quantification of relative EEG band power in the mCherry group during maintenance. J Behavioral arousal scores during propofol maintenance in ChR2 and mCherry mice. K Representative EEG spectrogram and EEG/EMG traces during emergence in the ChR2 group. L Group-averaged EEG power spectra (0–30 Hz) in the ChR2 group during emergence. M Quantification of relative EEG band power in the ChR2 group during emergence. N Representative EEG spectrogram and EEG/EMG traces during emergence in the mCherry group. O Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during emergence. P Quantification of relative EEG band power in the mCherry group during emergence. Q RORR latency after propofol discontinuation in mCherry and ChR2 mice with or without photostimulation. n = 8 mice per group. Data are presented as mean ± SEM. Statistical analysis was conducted using one-way repeated-measures ANOVA with Bonferroni post hoc test (F, I, M, P), Mann–Whitney U test (J), and one-way ANOVA (Q). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant Optogenetic activation of STN CaMKIIα-expressing neurons induces EEG and behavioral arousal during propofol anesthesia. A Diagram of viral delivery. C57BL/6 mice received bilateral injections of AAV-CaMKIIα-ChR2-mCherry or control AAV-CaMKIIα-mCherry into the STN. B Left, four weeks later, optical fibers and EEG/EMG electrodes were implanted. Right, representative histological image confirming ChR2-mCherry expression and fiber track placement in the STN. Scale bar, 100 μm. C Experimental protocol for propofol anesthesia. Following LORR, propofol was maintained at 2 mg/kg/min. Red dashed boxes indicate photostimulation (465 nm, 20 Hz, 10 ms pulse width, 180 s, 5 mW at the fiber tip) during the maintenance phase, and green dashed boxes indicate identical stimulation applied shortly before emergence. D Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after photostimulation during maintenance in the ChR2 group. E Group-averaged EEG power spectra (0–30 Hz) in the ChR2 group across pre-, stimulation-, and post-stimulation periods. F Quantification of relative EEG band power (delta, theta, alpha, beta) in the ChR2 group during maintenance. G Representative EEG spectrogram and EEG/EMG traces in the mCherry control group. H Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during maintenance. I Quantification of relative EEG band power in the mCherry group during maintenance. J Behavioral arousal scores during propofol maintenance in ChR2 and mCherry mice. K Representative EEG spectrogram and EEG/EMG traces during emergence in the ChR2 group. L Group-averaged EEG power spectra (0–30 Hz) in the ChR2 group during emergence. M Quantification of relative EEG band power in the ChR2 group during emergence. N Representative EEG spectrogram and EEG/EMG traces during emergence in the mCherry group. O Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during emergence. P Quantification of relative EEG band power in the mCherry group during emergence. Q RORR latency after propofol discontinuation in mCherry and ChR2 mice with or without photostimulation. n = 8 mice per group. Data are presented as mean ± SEM. Statistical analysis was conducted using one-way repeated-measures ANOVA with Bonferroni post hoc test (F, I, M, P), Mann–Whitney U test (J), and one-way ANOVA (Q). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant During propofol maintenance, optogenetic activation of STN CaMKIIα-expressing neurons triggered immediate behavioral arousal. EEG activity rapidly shifted from high-amplitude slow waves to low-voltage, faster rhythms, accompanied by increased EMG activity (Fig. 2D). Power spectral analysis demonstrated that photostimulation decreased delta power and increased theta and alpha power during the stimulation period (Fig. 2E, F; pre vs. stimulation: delta:51.53 ± 4.87% vs. 40.82 ± 3.52%, P < 0.0001; theta: 29.43 ± 6.84% vs. 34.33 ± 3.60%, P = 0.0188; alpha: 7.47 ± 1.91% vs. 15.38 ± 2.21%, P = 0.0005). After stimulation ended, these changes were partially reversed (Fig. 2E, F; stimulation vs. post-stimulation: delta:40.82 ± 3.52% vs. 48.52 ± 3.16%, P < 0.0001; alpha: 15.38 ± 2.21% vs. 9.44 ± 2.55%, P = 0.0032). In contrast, no significant EEG or EMG changes were observed in mCherry control mice across the pre-stimulation, stimulation, and post-stimulation periods (Fig. 2G–I; P > 0.05). Consistent with these electrophysiological findings, activation of STN CaMKIIα-expressing neurons evoked robust arousal behaviors, which were not observed in controls (Fig. 2J; ChR2 vs. mCherry: 4.88 ± 1.89 vs. 0.13 ± 0.35, P = 0.0002). To further assess the role of these neurons in emergence from propofol anesthesia, optical stimulation was applied immediately after discontinuation of propofol. In ChR2-expressing mice, optogenetic activation of STN CaMKIIα-expressing neurons induced a rapid EEG transition from high-amplitude slow waves to low-voltage, faster activity, accompanied by increased EMG tone (Fig. 2K). EEG changes induced by photostimulation delivered immediately after propofol withdrawal were analyzed. Compared with the pre-stimulation period, photostimulation significantly reduced delta power and increased theta and alpha power (Fig. 2L, M; pre vs. stimulation: delta, 51.65 ± 5.14% vs. 40.53 ± 2.97%, P < 0.0001; theta, 31.97 ± 3.24% vs. 36.21 ± 1.99%, P = 0.0188; alpha, 7.83 ± 1.94% vs. 15.13 ± 2.02%, P = 0.0005), and these effects persisted after stimulation ended (Fig. 2L, M; pre vs. post stimulation: delta, 51.65 ± 5.14% vs. 37.47 ± 3.13%, P < 0.0001; theta, 31.97 ± 3.24% vs. 36.90 ± 4.17%, P = 0.0082; alpha, 7.83 ± 1.94% vs. 12.33 ± 3.48%, P = 0.0184). No significant EEG or EMG changes were detected in control mice across the three epochs (Fig. 2N–P; P > 0.05). Importantly, optogenetic activation of STN CaMKIIα-expressing neurons significantly shortened RORR latency from anesthesia (Fig. 2Q; ChR2 on vs. ChR2 off: 228.00 ± 90.90 s vs. 585.88 ± 137.24 s, P = 0.0007). Collectively, the data support that activation of STN CaMKIIα-expressing neurons enhances arousal-related behavior and promotes a wake-like cortical state during both maintained anesthesia and emergence. Chemogenetic activation of STN CaMKIIα-expressing neurons accelerates emergence without altering induction during propofol anesthesia Previous studies suggest that anesthesia induction and subsequent emergence do not depend on identical neural substrates. A chemogenetic strategy was therefore used to determine whether STN CaMKIIα-expressing neurons contribute to both propofol-induced loss of righting reflex and behavioral emergence. AAV-CaMKIIα-hM3Dq-mCherry or control AAV-CaMKIIα-mCherry was bilaterally injected into the STN of C57BL/6 mice, followed by implantation of EEG–EMG electrodes (Fig. 3A). Following systemic administration of CNO, c-Fos immunostaining demonstrated robust activation of hM3Dq-expressing neurons in the STN (Fig. 3B, C; mCherry-CNO vs. hM3Dq-CNO:14.33 ± 2.33 vs. 82.67 ± 2.73, P < 0.001).Fig. 3Chemogenetic activation of STN CaMKIIα-expressing neurons facilitates emergence without affecting induction during propofol anesthesia. A Diagram of viral injection and EEG/EMG electrode implantation. C57BL/6 mice received bilateral injections of AAV-CaMKIIα-hM3Dq-mCherry or control AAV-CaMKIIα-mCherry into the STN, followed by electrode placement. B Representative immunofluorescence images of the STN showing hM3Dq-mCherry expression and c-Fos labeling after CNO administration. Scale bars, 200 μm. C Quantification of the proportion of virus-labeled neurons expressing c-Fos in the STN following CNO administration. D Experimental design for the induction protocol. Mice received CNO or saline (3 mg/kg, i.p.) 30 min before propofol infusion (10 mg/kg/min), after which EEG activity during induction and LORR latency were assessed. E, F Representative EEG power spectra and EEG–EMG traces from hM3Dq-CNO mice (E) and mCherry-CNO mice (F) during induction. G Group-level EEG power spectral density during induction across experimental groups. Middle and right panels show representative PSD distributions from control and hM3Dq-CNO groups. H Quantification of relative EEG band power during induction in mCherry-CNO and hM3Dq-CNO mice. I Statistical comparison of LORR latency among groups during induction. J Experimental design for the maintenance/emergence protocol. After LORR, propofol was maintained at 2 mg/kg/min; CNO or saline (3 mg/kg, i.p.) was administered 30 min after stable anesthesia, EEG was analyzed during emergence, and RORR latency was measured. K, L Representative EEG power spectra and EEG–EMG traces from hM3Dq-CNO mice (K) and mCherry-CNO mice (L) during emergence. M Group EEG power spectral density during emergence across experimental groups. Middle and right panels show representative PSD distributions. N Quantification of relative EEG band power during emergence in mCherry-CNO and hM3Dq-CNO mice. O Statistical comparison of RORR latency among groups. n = 8 mice per group. Data are expressed as mean ± SEM. Statistical tests included unpaired t-test (C, H, N) and one-way ANOVA (I, O). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant Chemogenetic activation of STN CaMKIIα-expressing neurons facilitates emergence without affecting induction during propofol anesthesia. A Diagram of viral injection and EEG/EMG electrode implantation. C57BL/6 mice received bilateral injections of AAV-CaMKIIα-hM3Dq-mCherry or control AAV-CaMKIIα-mCherry into the STN, followed by electrode placement. B Representative immunofluorescence images of the STN showing hM3Dq-mCherry expression and c-Fos labeling after CNO administration. Scale bars, 200 μm. C Quantification of the proportion of virus-labeled neurons expressing c-Fos in the STN following CNO administration. D Experimental design for the induction protocol. Mice received CNO or saline (3 mg/kg, i.p.) 30 min before propofol infusion (10 mg/kg/min), after which EEG activity during induction and LORR latency were assessed. E, F Representative EEG power spectra and EEG–EMG traces from hM3Dq-CNO mice (E) and mCherry-CNO mice (F) during induction. G Group-level EEG power spectral density during induction across experimental groups. Middle and right panels show representative PSD distributions from control and hM3Dq-CNO groups. H Quantification of relative EEG band power during induction in mCherry-CNO and hM3Dq-CNO mice. I Statistical comparison of LORR latency among groups during induction. J Experimental design for the maintenance/emergence protocol. After LORR, propofol was maintained at 2 mg/kg/min; CNO or saline (3 mg/kg, i.p.) was administered 30 min after stable anesthesia, EEG was analyzed during emergence, and RORR latency was measured. K, L Representative EEG power spectra and EEG–EMG traces from hM3Dq-CNO mice (K) and mCherry-CNO mice (L) during emergence. M Group EEG power spectral density during emergence across experimental groups. Middle and right panels show representative PSD distributions. N Quantification of relative EEG band power during emergence in mCherry-CNO and hM3Dq-CNO mice. O Statistical comparison of RORR latency among groups. n = 8 mice per group. Data are expressed as mean ± SEM. Statistical tests included unpaired t-test (C, H, N) and one-way ANOVA (I, O). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant To determine whether activation of STN CaMKIIα-expressing neurons influences anesthesia induction, CNO or saline was administered intraperitoneally 30 min prior to propofol infusion (Fig. 3D). Representative EEG–EMG recordings from hM3Dq-CNO and mCherry-CNO mice during the induction phase are presented in Fig. 3E and F. Group-level power spectral analysis and quantification of relative band power showed no significant differences in induction-related EEG features among the experimental groups (Fig. 3G, H; P > 0.05). Consistent with these findings, LORR latency did not differ significantly across groups (Fig. 3I; P > 0.05). These results indicate that chemogenetic stimulation of STN CaMKIIα-expressing neurons does not measurably affect propofol induction. We next assessed whether sustained activation of STN CaMKIIα-expressing neurons modulates emergence from propofol anesthesia. CNO was administered 30 min after stable propofol anesthesia had been established (Fig. 3J). Representative EEG–EMG traces indicated that hM3Dq-CNO mice exhibited an earlier transition from high-amplitude slow activity to lower-voltage faster rhythms, accompanied by increased EMG tone, whereas mCherry-CNO mice did not display a comparable response (Fig. 3K, L). Power spectral analysis further showed that hM3Dq-CNO mice exhibited decreased delta power and increased theta power compared with control groups (Fig. 3M, N; mCherry-CNO vs. hM3Dq-CNO: delta, 44.65 ± 1.48% vs. 33.78 ± 2.82%, P < 0.001; theta, 31.83 ± 4.08% vs. 42.73 ± 5.86%, P < 0.001). In addition, RORR latency was significantly shortened in hM3Dq-CNO mice relative to controls (Fig. 3O; mCherry-CNO vs. hM3Dq-CNO:753.13 ± 314.72 s vs. 65.63 ± 38.04 s, P < 0.001). Collectively, these findings suggest that chemogenetic activation of STN CaMKIIα-expressing neurons facilitates behavioral emergence from propofol anesthesia without altering the induction process. Optogenetic inhibition of STN CaMKIIα-expressing neurons enhances cortical suppression and delays emergence during propofol anesthesia The next step was to determine whether inhibition of STN CaMKIIα-expressing neurons further suppresses cortical activity during propofol anesthesia. AAV-CaMKIIα-eNpHR3.0-mCherry or control AAV-CaMKIIα-mCherry was bilaterally injected into the STN (Fig. 4A). After three weeks of viral expression, mice underwent concurrent implantation of EEG–EMG electrodes and optical fibers. (Fig. 4B, left). Histology images verified robust eNpHR3.0-mCherry expression in STN CaMKIIα-expressing neurons (Fig. 4B, right). Optical stimulation was then delivered at two time points: 30 min after establishing stable propofol maintenance and immediately after propofol withdrawal (Fig. 4C).Fig. 4Optogenetic inhibition of STN CaMKIIα-expressing neurons enhances EEG slowing during propofol anesthesia and delays emergence. A Diagram of viral injection. C57BL/6 mice received bilateral STN injections of AAV-CaMKIIα-eNpHR-mCherry or control AAV-CaMKIIα-mCherry. B Left, four weeks later, optical fibers and EEG/EMG electrodes were implanted. Right, representative histological image showing eNpHR-mCherry expression and fiber placement in the STN. Scale bar, 100 μm. C Experimental design for propofol anesthesia. Following LORR, propofol was maintained at 2 mg/kg/min. Red dashed boxes indicate yellow-light stimulation (589 nm, 1-s pulses, 180 s, 5 mW at the fiber tip) during maintenance, and green dashed boxes indicate stimulation applied before emergence. D Representative EEG spectrogram and EEG/EMG traces during maintenance in the eNpHR group. E Group-averaged EEG power spectra (0–30 Hz) in the eNpHR group across experimental periods. F Quantification of relative EEG band power in the eNpHR group during maintenance. G Representative EEG spectrogram and EEG/EMG traces in the mCherry control group. H Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during maintenance. I Quantification of relative EEG band power in the mCherry group during maintenance. J Representative EEG spectrogram and EEG/EMG traces during emergence in the eNpHR group. K Group-averaged EEG power spectra (0–30 Hz) in the eNpHR group during emergence. L Quantification of relative EEG band power in the eNpHR group during emergence. M Representative EEG spectrogram and EEG/EMG traces in the mCherry group during emergence. N Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during emergence. O Quantification of relative EEG band power in the mCherry group during emergence. P RORR latency after propofol discontinuation in mCherry and eNpHR mice with or without light stimulation. n = 8 mice per group. Data are expressed as mean ± SEM. Statistical analyses were conducted using one-way repeated-measures ANOVA with Bonferroni post hoc test (F, I, L, O) and one-way ANOVA (P). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant Optogenetic inhibition of STN CaMKIIα-expressing neurons enhances EEG slowing during propofol anesthesia and delays emergence. A Diagram of viral injection. C57BL/6 mice received bilateral STN injections of AAV-CaMKIIα-eNpHR-mCherry or control AAV-CaMKIIα-mCherry. B Left, four weeks later, optical fibers and EEG/EMG electrodes were implanted. Right, representative histological image showing eNpHR-mCherry expression and fiber placement in the STN. Scale bar, 100 μm. C Experimental design for propofol anesthesia. Following LORR, propofol was maintained at 2 mg/kg/min. Red dashed boxes indicate yellow-light stimulation (589 nm, 1-s pulses, 180 s, 5 mW at the fiber tip) during maintenance, and green dashed boxes indicate stimulation applied before emergence. D Representative EEG spectrogram and EEG/EMG traces during maintenance in the eNpHR group. E Group-averaged EEG power spectra (0–30 Hz) in the eNpHR group across experimental periods. F Quantification of relative EEG band power in the eNpHR group during maintenance. G Representative EEG spectrogram and EEG/EMG traces in the mCherry control group. H Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during maintenance. I Quantification of relative EEG band power in the mCherry group during maintenance. J Representative EEG spectrogram and EEG/EMG traces during emergence in the eNpHR group. K Group-averaged EEG power spectra (0–30 Hz) in the eNpHR group during emergence. L Quantification of relative EEG band power in the eNpHR group during emergence. M Representative EEG spectrogram and EEG/EMG traces in the mCherry group during emergence. N Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during emergence. O Quantification of relative EEG band power in the mCherry group during emergence. P RORR latency after propofol discontinuation in mCherry and eNpHR mice with or without light stimulation. n = 8 mice per group. Data are expressed as mean ± SEM. Statistical analyses were conducted using one-way repeated-measures ANOVA with Bonferroni post hoc test (F, I, L, O) and one-way ANOVA (P). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant During the maintenance phase, optogenetic inhibition of STN CaMKIIα-expressing neurons induced a clear EEG transition from relatively low-voltage fast activity to higher-amplitude slow activity (Fig. 4D). Power spectral analysis across the pre-stimulation, stimulation, and post-stimulation epochs demonstrated that photoinhibition increased delta power during the stimulation period (Fig. 4E, F; pre vs. stimulation: 48.06 ± 2.78% vs. 53.31 ± 1.97%, P = 0.006). After stimulation ended, these changes returned toward pre-stimulation levels. In contrast, control mice exhibited no significant EEG or EMG changes across the three epochs (Fig. 4G–I; P > 0.05). During the emergence phase, 180 s of photoinhibition delivered immediately after propofol withdrawal markedly restrained the normal EEG transition toward desynchronization in eNpHR3.0-expressing mice (Fig. 4J). Spectral analysis across the pre-stimulation, stimulation, and post-stimulation epochs showed that inhibitory stimulation increased delta power during the stimulation period (Fig. 4K, L; pre vs. stimulation, 50.18 ± 4.02% vs. 56.07 ± 3.38%, P = 0.0037), and this effect decreased after the laser was turned off, with post-stimulation values returning toward baseline (Fig. 4K, L; stimulation vs. post-stimulation, 56.07 ± 3.38% vs. 50.08 ± 3.39%). In contrast, mCherry control mice showed no significant EEG or EMG changes across the three epochs (Fig. 4M–O; P > 0.05). Consistent with these electrophysiological observations, photoinhibition of STN CaMKIIα-expressing neurons significantly prolonged RORR latency in eNpHR mice, whereas light delivery did not significantly alter RORR latency in mCherry controls (Fig. 4P; 1565.00 ± 426.26 s vs. 481.00 ± 247.78 s, P < 0.001). Overall, these findings indicate that inhibition of STN CaMKIIα-expressing neurons enhances cortical suppression and delays emergence from propofol anesthesia. Chemogenetic inhibition of STN CaMKIIα-expressing neurons delays emergence without altering induction during propofol anesthesia To evaluate the effects of sustained inhibition, AAV-CaMKIIα-hM4Di-mCherry or control AAV-CaMKIIα-mCherry was bilaterally injected into the STN of C57BL/6 mice. After three weeks of viral expression, mice underwent concurrent implantation of EEG–EMG electrodes (Fig. 5A). Following systemic administration of CNO, the proportion of virus-labeled neurons expressing c-Fos was significantly lower in the hM4Di group compared with the mCherry control group (Fig. 5B, C; mCherry-CNO vs. hM4Di-CNO: 14.33 ± 2.33 vs. 3.33 ± 0.88, P = 0.0116), confirming effective suppression of hM4Di-expressing neurons in vivo.Fig. 5Chemogenetic inhibition of STN CaMKIIα-expressing neurons delays emergence while not affecting induction during propofol anesthesia. A Schematic illustrating viral injection and EEG/EMG electrode placement. C57BL/6 mice received bilateral STN injections of AAV-CaMKIIα-hM4Di-mCherry or control AAV-CaMKIIα-mCherry, followed by implantation of cortical EEG and neck EMG electrodes. B Representative immunofluorescence images of the STN showing hM4Di-mCherry expression together with c-Fos labeling after CNO administration. Scale bars, 200 μm. C Quantification of the proportion of virus-labeled neurons expressing c-Fos in the STN following systemic CNO administration. D Experimental design for the induction protocol. Mice were administered CNO (3 mg/kg, i.p.) 30 min prior to propofol infusion (10 mg/kg/min), after which EEG activity during induction and LORR latency were evaluated. E, F Representative EEG power spectra and EEG–EMG traces from hM4Di-CNO mice (E) and mCherry-CNO mice (F) during induction. G Group-level EEG power spectral density during induction across hM4Di-saline, hM4Di-CNO, mCherry-saline, and mCherry-CNO groups. Right, representative PSD distributions from control and hM4Di-CNO mice. H Quantification of relative EEG band power (delta, theta, alpha, beta) during induction in mCherry-CNO and hM4Di-CNO mice. I Statistical comparison of LORR latency among the four groups during induction. J Experimental design for the maintenance/emergence protocol. After LORR, propofol was maintained at 2 mg/kg/min; CNO (3 mg/kg, i.p.) was administered 30 min after stable anesthesia, and EEG was analyzed during emergence until RORR. K, L Representative EEG power spectra and EEG–EMG traces from hM4Di-CNO mice (K) and mCherry-CNO mice (L) during emergence. M Group EEG power spectral density during emergence across experimental groups. Right, representative PSD distributions from control and hM4Di-CNO mice. N Quantification of relative EEG band power during emergence in mCherry-CNO and hM4Di-CNO mice. O Statistical comparison of RORR latency among groups. n = 8 mice per group. Data are expressed as mean ± SEM. Statistical analysis was performed using unpaired t-test (C, H, N) and one-way ANOVA (I, O). *P < 0.05, **P < 0.01, ***P < 0.001 Chemogenetic inhibition of STN CaMKIIα-expressing neurons delays emergence while not affecting induction during propofol anesthesia. A Schematic illustrating viral injection and EEG/EMG electrode placement. C57BL/6 mice received bilateral STN injections of AAV-CaMKIIα-hM4Di-mCherry or control AAV-CaMKIIα-mCherry, followed by implantation of cortical EEG and neck EMG electrodes. B Representative immunofluorescence images of the STN showing hM4Di-mCherry expression together with c-Fos labeling after CNO administration. Scale bars, 200 μm. C Quantification of the proportion of virus-labeled neurons expressing c-Fos in the STN following systemic CNO administration. D Experimental design for the induction protocol. Mice were administered CNO (3 mg/kg, i.p.) 30 min prior to propofol infusion (10 mg/kg/min), after which EEG activity during induction and LORR latency were evaluated. E, F Representative EEG power spectra and EEG–EMG traces from hM4Di-CNO mice (E) and mCherry-CNO mice (F) during induction. G Group-level EEG power spectral density during induction across hM4Di-saline, hM4Di-CNO, mCherry-saline, and mCherry-CNO groups. Right, representative PSD distributions from control and hM4Di-CNO mice. H Quantification of relative EEG band power (delta, theta, alpha, beta) during induction in mCherry-CNO and hM4Di-CNO mice. I Statistical comparison of LORR latency among the four groups during induction. J Experimental design for the maintenance/emergence protocol. After LORR, propofol was maintained at 2 mg/kg/min; CNO (3 mg/kg, i.p.) was administered 30 min after stable anesthesia, and EEG was analyzed during emergence until RORR. K, L Representative EEG power spectra and EEG–EMG traces from hM4Di-CNO mice (K) and mCherry-CNO mice (L) during emergence. M Group EEG power spectral density during emergence across experimental groups. Right, representative PSD distributions from control and hM4Di-CNO mice. N Quantification of relative EEG band power during emergence in mCherry-CNO and hM4Di-CNO mice. O Statistical comparison of RORR latency among groups. n = 8 mice per group. Data are expressed as mean ± SEM. Statistical analysis was performed using unpaired t-test (C, H, N) and one-way ANOVA (I, O). *P < 0.05, **P < 0.01, ***P < 0.001 As in the chemogenetic activation experiments, CNO or saline was administered intraperitoneally 30 min prior to propofol induction to evaluate whether inhibition of STN CaMKIIα-expressing neurons affects anesthesia induction (Fig. 5D). Typical EEG–EMG traces during anesthesia induction in hM4Di‑CNO and mCherry‑CNO mice are presented in Fig. 5E and F. Group-level power spectral analysis and quantification of relative EEG band power revealed no significant differences among groups during induction (Fig. 5G, H; P > 0.05). Consistently, LORR latency did not differ significantly across groups (Fig. 5I; P > 0.05). The effects of sustained inhibition during the emergence phase were then examined. CNO or saline was injected intraperitoneally 30 min after stable propofol anesthesia had been established (Fig. 5J). Compared with mCherry-CNO mice, hM4Di-CNO mice exhibited delayed EEG desynchronization during emergence, as illustrated by representative EEG–EMG traces (Fig. 5K and L). Group power spectral analysis further showed that hM4Di-CNO mice displayed increased delta power during emergence, whereas theta, alpha, and beta power were not significantly altered (Fig. 5M, N; mCherry-CNO vs. hM4Di-CNO, 44.65 ± 1.48% vs. 49.39 ± 3.27%, P = 0.0091). In addition, RORR latency was significantly prolonged in hM4Di-CNO mice compared with control groups (Fig. 5O; mCherry-CNO vs. hM4Di-CNO:753.13 ± 314.72 s vs. 1210.38 ± 324.35 s, P = 0.0314). Taken together, these findings indicate that sustained inhibition of STN CaMKIIα-expressing neurons selectively delays emergence from propofol anesthesia without affecting induction. Axonal projection pattern of STN CaMKIIα-expressing neurons To identify downstream targets of STN CaMKIIα-expressing neurons, we injected a mixture of AAV-CaMKIIα-Cre and AAV DIO-EGFP into the STN of C57BL/6 mice (Fig. 6A). Under the CaMKIIα promoter, EGFP expression was restricted to CaMKIIα-expressing neurons (Fig. 6B). Analysis of serial coronal sections revealed widespread efferent projections from the STN (Fig. 6C, D), with strong signals in the substantia nigra, external and internal globus pallidus (GPe and GPi), ventral pallidum (VP), lateral habenula (LHb), and parabrachial nucleus (PBN). To further verify direct connectivity between STN CaMKIIα-expressing neurons and the VP, we injected a mixture of Retro-DIO-EGFP and CTB555 into the VP and delivered AAV-CaMKIIα-Cre into the STN (Fig. 6E, F). Retrograde labeling confirmed that CaMKIIα-expressing neurons in the ventromedial STN project directly to the VP (Fig. 6G).Fig. 6Anterograde and retrograde tracing of projections from STN CaMKIIα-expressing neurons. A C57BL/6 mice received co-injection of AAV-CaMKIIα-Cre and Cre-dependent DIO-EGFP into the STN. B Representative coronal section showing EGFP expression driven by CaMKIIα restricted within the STN. Scale bar, 200 μm. C Representative images of EGFP-labeled axonal projections in downstream brain regions at different rostrocaudal levels (Bregma coordinates indicated above each panel), including ventral pallidum (VP), lateral and medial globus pallidus (LGP, MGP), lateral habenula (LHb), substantia nigra pars compacta and reticulata (SNc, SNr), parasubthalamic nucleus (PSTN), ventral tegmental area (VTA), pedunculopontine tegmental nucleus (PPTg), lateral parabrachial nucleus (LPB), and medial parabrachial nucleus (MPB). Scale bars, 200 μm. D Summary diagram showing relative projection intensity from STN neurons to indicated target regions. E Schematic of AAV-Retro-DIO-EGFP injection into the VP combined with AAV-CaMKIIα-Cre delivery into the STN of C57BL/6 mice. F Representative coronal sections showing CTB-555 labeling within the VP at different Bregma levels. Scale bars, 200 μm. G Serial coronal sections from a representative mouse showing EGFP-labeled neurons across the entire STN. Scale bars, 100 μm Anterograde and retrograde tracing of projections from STN CaMKIIα-expressing neurons. A C57BL/6 mice received co-injection of AAV-CaMKIIα-Cre and Cre-dependent DIO-EGFP into the STN. B Representative coronal section showing EGFP expression driven by CaMKIIα restricted within the STN. Scale bar, 200 μm. C Representative images of EGFP-labeled axonal projections in downstream brain regions at different rostrocaudal levels (Bregma coordinates indicated above each panel), including ventral pallidum (VP), lateral and medial globus pallidus (LGP, MGP), lateral habenula (LHb), substantia nigra pars compacta and reticulata (SNc, SNr), parasubthalamic nucleus (PSTN), ventral tegmental area (VTA), pedunculopontine tegmental nucleus (PPTg), lateral parabrachial nucleus (LPB), and medial parabrachial nucleus (MPB). Scale bars, 200 μm. D Summary diagram showing relative projection intensity from STN neurons to indicated target regions. E Schematic of AAV-Retro-DIO-EGFP injection into the VP combined with AAV-CaMKIIα-Cre delivery into the STN of C57BL/6 mice. F Representative coronal sections showing CTB-555 labeling within the VP at different Bregma levels. Scale bars, 200 μm. G Serial coronal sections from a representative mouse showing EGFP-labeled neurons across the entire STN. Scale bars, 100 μm Stimulation of CaMKIIα-expressing neuronal projections from the STN to the VP promotes behavioral emergence and cortical activation during propofol anesthesia The VP functions as a central hub in regulating anesthetic emergence, and previous studies, together with the present tracing data, indicate that the VP receives dense input from STN CaMKIIα-expressing neurons. The effect of activating STN CaMKIIα-expressing axon terminals in the VP on propofol anesthesia was therefore examined. Three weeks after unilateral transduction of AAV-CaMKIIα-ChR2-mCherry into the STN, an optical fiber was stereotaxically positioned above the VP, while EEG–EMG electrodes were implanted concurrently over the cortex and in the neck musculature (Fig. 7A). Histological analysis verified robust ChR2-mCherry expression in STN CaMKIIα-expressing neurons and accurate placement of the optical fiber in the VP (Fig. 7B). During both the maintenance and emergence phases of propofol anesthesia, STN–VP projections were activated using optogenetic stimulation at 5 mW and 20 Hz (Fig. 7C). During the maintenance phase, optogenetic activation of STN CaMKIIα-expressing axon terminals in the VP rapidly evoked behavioral arousal, accompanied by pronounced changes in EEG–EMG activity (Fig. 7D). Power spectral analysis across the pre-stimulation, stimulation, and post-stimulation epochs demonstrated that photostimulation reduced delta power and increased theta power during the stimulation period (Fig. 7E, F; pre vs. stimulation: delta, 50.80 ± 4.76% vs. 34.84 ± 3.74%, P < 0.001; theta, 29.73 ± 5.70 vs. 39.39 ± 8.82%, P < 0.001). After stimulation ended, delta power remained lower than the pre-stimulation level, whereas theta power gradually returned toward baseline (pre vs. post-stimulation: delta, 50.80 ± 4.76% vs. 43.08 ± 4.97%, P = 0.004). In contrast, mCherry control mice exhibited no significant EEG or EMG changes across the three epochs (Fig. 7G–I; P > 0.05). Consistent with these findings, optical activation of STN–VP axon terminals induced robust arousal-like behaviors in ChR2 mice but not in controls (Fig. 7J; ChR2-on vs. mCherry-on: 5.50 ± 2.83 vs. 0.13 ± 0.35, P = 0.0002).Fig. 7Optogenetic activation of STN CaMKIIα-expressing projections to the ventral pallidum induces behavioral and EEG arousal during propofol anesthesia. A Schematic of the experimental setup. C57BL/6 mice received STN injections of AAV-CaMKIIα-ChR2-mCherry or control AAV-CaMKIIα-mCherry. An optical fiber was positioned above the ventral pallidum (VP), along with implantation of cortical EEG and neck EMG electrodes. B Representative histological images showing ChR2-mCherry expression in the STN (left) and labeled axon terminals together with fiber placement in the VP (right). Scale bars, 200 μm. C Experimental protocol for propofol anesthesia. After LORR, propofol was maintained at 2 mg/kg/min. Blue light stimulation (20 Hz, 10 ms pulse width, 5 mW) was applied during the maintenance phase (red dashed box) and shortly before emergence (green dashed box). D Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after photostimulation during maintenance in the ChR2 group. E Group-averaged EEG power spectra (0–30 Hz) in the ChR2 group across pre-, stimulation-, and post-stimulation periods during maintenance. F Quantification of relative EEG band power in the ChR2 group during maintenance. G Representative EEG spectrogram and EEG/EMG traces in the mCherry control group. H Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during maintenance. I Quantification of relative EEG band power in the mCherry group during maintenance. J Behavioral arousal scores during propofol maintenance in ChR2 and mCherry mice. K Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after photostimulation during the emergence phase in the ChR2 group. L Group-averaged EEG power spectra (0–30 Hz) in the ChR2 group during emergence. M Quantification of relative EEG band power in the ChR2 group during emergence. N Representative EEG spectrogram and EEG/EMG traces in the mCherry control group during emergence. O Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during emergence. P Quantification of relative EEG band power in the mCherry group during emergence. Q RORR latency after propofol discontinuation in mCherry and ChR2 mice with or without photostimulation. n = 8 mice per group. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way repeated-measures ANOVA with Bonferroni post hoc test (F, I, M, P), Mann–Whitney U test (J), and one-way ANOVA (Q). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant Optogenetic activation of STN CaMKIIα-expressing projections to the ventral pallidum induces behavioral and EEG arousal during propofol anesthesia. A Schematic of the experimental setup. C57BL/6 mice received STN injections of AAV-CaMKIIα-ChR2-mCherry or control AAV-CaMKIIα-mCherry. An optical fiber was positioned above the ventral pallidum (VP), along with implantation of cortical EEG and neck EMG electrodes. B Representative histological images showing ChR2-mCherry expression in the STN (left) and labeled axon terminals together with fiber placement in the VP (right). Scale bars, 200 μm. C Experimental protocol for propofol anesthesia. After LORR, propofol was maintained at 2 mg/kg/min. Blue light stimulation (20 Hz, 10 ms pulse width, 5 mW) was applied during the maintenance phase (red dashed box) and shortly before emergence (green dashed box). D Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after photostimulation during maintenance in the ChR2 group. E Group-averaged EEG power spectra (0–30 Hz) in the ChR2 group across pre-, stimulation-, and post-stimulation periods during maintenance. F Quantification of relative EEG band power in the ChR2 group during maintenance. G Representative EEG spectrogram and EEG/EMG traces in the mCherry control group. H Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during maintenance. I Quantification of relative EEG band power in the mCherry group during maintenance. J Behavioral arousal scores during propofol maintenance in ChR2 and mCherry mice. K Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after photostimulation during the emergence phase in the ChR2 group. L Group-averaged EEG power spectra (0–30 Hz) in the ChR2 group during emergence. M Quantification of relative EEG band power in the ChR2 group during emergence. N Representative EEG spectrogram and EEG/EMG traces in the mCherry control group during emergence. O Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during emergence. P Quantification of relative EEG band power in the mCherry group during emergence. Q RORR latency after propofol discontinuation in mCherry and ChR2 mice with or without photostimulation. n = 8 mice per group. Data are presented as mean ± SEM. Statistical analyses were conducted using one-way repeated-measures ANOVA with Bonferroni post hoc test (F, I, M, P), Mann–Whitney U test (J), and one-way ANOVA (Q). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant To further determine the role of the STN–VP circuit in anesthetic emergence, axon terminals of STN CaMKIIα-expressing neurons in the VP were activated immediately after termination of propofol infusion (Fig. 7K–M). Optogenetic stimulation of ChR2-mCherry-expressing STN CaMKIIα-expressing axon terminals rapidly triggered behavioral arousal, characterized by EEG desynchronization with low-amplitude fast activity and a marked increase in EMG tone (Fig. 7K). Power spectral analysis indicated that stimulation significantly decreased delta power while increasing theta and alpha power during the stimulation period (Fig. 7L, M; pre vs. stimulation: delta, 51.57 ± 6.82% vs. 40.31 ± 3.47%, P < 0.001; theta, 29.36 ± 4.69% vs. 34.81 ± 4.68%, P = 0.0139; alpha, 15.20 ± 1.83% vs. 22.41 ± 2.89%, P < 0.001). Notably, enhancement of theta and alpha activity persisted after stimulation ended, whereas delta power remained reduced relative to the pre-stimulation level (pre vs. post-stimulation: delta, 51.57 ± 6.82% vs. 36.93 ± 3.51%, P < 0.001; theta, 29.36 ± 4.69% vs. 36.75 ± 3.65%, P < 0.001; alpha, 15.20 ± 1.83% vs 20.70 ± 1.96%, P = 0.0127). In contrast, mCherry control mice showed no significant EEG or EMG changes across the pre-stimulation, stimulation, and post-stimulation epochs (Fig. 7N–P; P > 0.05). Importantly, Optogenetic stimulation of the STN–VP pathway significantly shortened RORR latency in ChR2 mice, whereas light delivery had no significant effect in mCherry controls (Fig. 7Q; 78.38 ± 125.84 s vs. 563.63 ± 176.05 s, P = 0.0004). Together, these findings demonstrate that activation of STN projections to the VP induces robust behavioral arousal and drives cortical activity toward an arousal-like pattern during both stable anesthesia and emergence. Inhibition of the STN–VP pathway enhances cortical suppression and delays emergence To determine whether suppression of the STN–VP pathway leads to the opposite effect, AAV-CaMKIIα-eNpHR3.0-mCherry was injected into the STN (Fig. 8A). Three weeks after unilateral transduction of AAV-CaMKIIα- eNpHR3.0-mCherry into the STN, an optical fiber was stereotaxically positioned above the VP, while EEG–EMG electrodes were implanted concurrently over the cortex and in the neck musculature (Fig. 8B). Histological analysis confirmed robust expression of eNpHR3.0-mCherry in STN CaMKIIα-expressing neurons and accurate positioning of the optical fiber in the VP. Optogenetic inhibition of STN CaMKIIα-expressing axon terminals in the VP was applied during both the anesthesia maintenance and emergence phases (Fig. 8C).Fig. 8Optogenetic inhibition of STN CaMKIIα-expressing projections to the ventral pallidum enhances EEG slowing during propofol anesthesia and prolongs emergence. A Schematic illustrating the experimental setup. C57BL/6 J mice received STN injections of AAV-CaMKIIα-eNpHR-mCherry or control AAV-CaMKIIα-mCherry. An optical fiber was positioned above the ventral pallidum (VP), together with implantation of cortical EEG and neck EMG electrodes. B Representative histological images showing eNpHR-mCherry expression in the STN (left) and labeled axon terminals with the fiber track in the VP (right). Scale bars, 200 μm. C Experimental protocol for propofol anesthesia. After LORR, propofol was maintained at 2 mg/kg/min. Yellow-light stimulation (589 nm, 1-s pulses, 180 s, 5 mW at the fiber tip) was applied during the maintenance phase (red dashed box) and shortly before emergence (green dashed box). D Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after light delivery during propofol-maintained anesthesia in the eNpHR group. E Group-averaged EEG power spectra (0–30 Hz) in the eNpHR group across pre-, stimulation-, and post-stimulation periods during maintenance. F Quantification of relative EEG band power (delta, theta, alpha, beta) in the eNpHR group during maintenance. G Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after light delivery in the mCherry control group. H Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during the maintenance phase. I Quantification of relative EEG band power in the mCherry group during maintenance. J Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after light delivery during the emergence phase in the eNpHR group. K Group-averaged EEG power spectra (0–30 Hz) in the eNpHR group during emergence across experimental periods. L Quantification of relative EEG band power in the eNpHR group during emergence. M Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after light delivery in the mCherry control group during emergence. N Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during the emergence phase. O Quantification of relative EEG band power in the mCherry group during emergence. P Latency to RORR following propofol discontinuation in mCherry and eNpHR mice with or without light stimulation. n = 8 mice per group. Data are expressed as mean ± SEM. Statistical analyses were conducted using one-way repeated-measures ANOVA with Bonferroni post hoc test (F, I, L, O) and one-way ANOVA (P). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant Optogenetic inhibition of STN CaMKIIα-expressing projections to the ventral pallidum enhances EEG slowing during propofol anesthesia and prolongs emergence. A Schematic illustrating the experimental setup. C57BL/6 J mice received STN injections of AAV-CaMKIIα-eNpHR-mCherry or control AAV-CaMKIIα-mCherry. An optical fiber was positioned above the ventral pallidum (VP), together with implantation of cortical EEG and neck EMG electrodes. B Representative histological images showing eNpHR-mCherry expression in the STN (left) and labeled axon terminals with the fiber track in the VP (right). Scale bars, 200 μm. C Experimental protocol for propofol anesthesia. After LORR, propofol was maintained at 2 mg/kg/min. Yellow-light stimulation (589 nm, 1-s pulses, 180 s, 5 mW at the fiber tip) was applied during the maintenance phase (red dashed box) and shortly before emergence (green dashed box). D Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after light delivery during propofol-maintained anesthesia in the eNpHR group. E Group-averaged EEG power spectra (0–30 Hz) in the eNpHR group across pre-, stimulation-, and post-stimulation periods during maintenance. F Quantification of relative EEG band power (delta, theta, alpha, beta) in the eNpHR group during maintenance. G Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after light delivery in the mCherry control group. H Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during the maintenance phase. I Quantification of relative EEG band power in the mCherry group during maintenance. J Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after light delivery during the emergence phase in the eNpHR group. K Group-averaged EEG power spectra (0–30 Hz) in the eNpHR group during emergence across experimental periods. L Quantification of relative EEG band power in the eNpHR group during emergence. M Representative EEG spectrogram and EEG/EMG traces recorded before, during, and after light delivery in the mCherry control group during emergence. N Group-averaged EEG power spectra (0–30 Hz) in the mCherry group during the emergence phase. O Quantification of relative EEG band power in the mCherry group during emergence. P Latency to RORR following propofol discontinuation in mCherry and eNpHR mice with or without light stimulation. n = 8 mice per group. Data are expressed as mean ± SEM. Statistical analyses were conducted using one-way repeated-measures ANOVA with Bonferroni post hoc test (F, I, L, O) and one-way ANOVA (P). ***P < 0.001, **P < 0.01, *P < 0.05; ns, not significant During the maintenance phase, photoinhibition induced a clear shift of EEG activity toward higher-amplitude slow-wave patterns in eNpHR3.0-expressing mice (Fig. 8D). Power spectral analysis across the pre-stimulation, stimulation, and post-stimulation epochs demonstrated that photoinhibition significantly increased delta power during the stimulation period (Fig. 8E, F; pre vs. stimulation: 49.07 ± 3.24% vs. 55.68 ± 3.25%, P < 0.001). In contrast, mCherry control mice showed no significant EEG or EMG changes across the three epochs (Fig. 8G–I; P > 0.05). During the emergence phase, 180 s of inhibitory stimulation delivered immediately after termination of propofol infusion delayed EEG desynchronization in the eNpHR-on group (Fig. 8J). Power spectral analysis across the pre-stimulation, stimulation, and post-stimulation epochs revealed that photoinhibition again significantly increased delta power during the stimulation period (Fig. 8K, L; pre vs. stimulation: 49.86 ± 3.17% vs. 56.56 ± 2.01%, P = 0.0038). In contrast, mCherry control mice exhibited no significant EEG or EMG changes across the three epochs (Fig. 8M–O; P > 0.05). Consistent with the EEG/EMG results, photoinhibition significantly delayed RORR in eNpHR mice, while the same light protocol produced no significant effect in mCherry control animals (Fig. 8P; 1507.75 ± 272.93 s vs. 666.75 ± 135.15 s, P < 0.001). Overall, these findings suggest that inhibition of the STN–VP pathway enhances cortical suppression and delays emergence from propofol anesthesia. Discussion STN–DBS has been shown to improve sleep architecture in patients with PD (Sharma et al. 2018), enhance subjective sleep quality and total sleep duration (Hjort et al. 2004; Lyons and Pahwa 2006), and reduce excessive somnolence (Bargiotas et al. 2017). Despite these observations, the role of the STN in the anesthesia-emergence cycle has remained insufficiently defined. In the present study, c-Fos immunohistochemistry and fiber photometry-based calcium recordings demonstrated that the population activity of STN CaMKIIα-expressing neurons is markedly suppressed during propofol-induced anesthesia. Using optogenetic and chemogenetic approaches, it was further shown that selective activation of these neurons reshapes EEG spectral dynamics during both anesthesia maintenance and emergence and significantly facilitates behavioral emergence from propofol anesthesia. These findings support STN CaMKIIα-expressing neurons as an important modulatory node in propofol-related brain-state transitions, particularly during emergence. Moreover, the results identify the STN–VP circuit as one pathway through which this effect is mediated. Collectively, this study indicates that STN CaMKIIα-expressing neurons contribute to arousal-related state transitions under propofol anesthesia, at least in part through engagement of the STN–VP projection. Consistent with previous studies of arousal circuits during anesthetic emergence (Luo et al. 2018a; Zecharia et al. 2012; Zhou et al. 2015), chemogenetic manipulation of STN CaMKIIα-expressing neurons did not affect the latency to LORR. In contrast, chemogenetic activation of STN CaMKIIα-expressing neurons through CNO administration during the maintenance phase rapidly reorganized EEG activity and significantly reduced RORR latency after propofol withdrawal. Several factors may account for this dissociation between induction and emergence. First, the induction rate of 10 mg/kg/min likely increases brain propofol concentrations beyond a threshold that produces widespread GABA_A receptor-mediated inhibition across the CNS, making activation of a local excitatory node such as the STN insufficient to counteract this global suppression. Consequently, modulation of the STN exerts minimal influence on anesthetic induction. Second, emergence from general anesthesia is not simply the reverse of induction; accumulating evidence indicates that these phases depend on distinct neural substrates (Kelz et al. 2008; Wang et al. 2021). Anesthetic agents induce unconsciousness by binding to specific molecular targets and disrupting normal neuronal firing patterns (Song and Hu 2024), whereas behavioral emergence reflects an active, endogenous process driven by intrinsic arousal systems. For instance, anesthesia-induced unconsciousness has been associated with rapid potassium-chloride cotransporter 2 (KCC2) degradation in the ventral posteromedial (VPM) nucleus (Hu et al. 2023), resulting in circuit reorganization and gradual restoration of cortical activity. These findings support the interpretation that STN CaMKIIα-expressing neurons primarily contribute to behavioral emergence rather than to anesthesia induction. Accumulating evidence suggests that anesthesia-related neural oscillations represent key signatures of the anesthetic state. Previous studies have shown that activation of arousal-promoting neurons consistently reduces delta and theta power while increasing alpha activity (Li et al. 2025; Wang et al. 2023; Zhou et al. 2024). In the present study, however, optogenetic activation of CaMKIIα-expressing neurons in the STN did not reduce theta band power; instead, a significant increase was observed, consistent with earlier reports (Li et al. 2022; Vazey and Aston-Jones 2014). Delta oscillations represent a defining electrophysiological feature of deep unconsciousness induced by GABAergic anesthetics such as propofol and reflect highly synchronized burst-suppression activity within cortico-thalamic networks (Purdon et al. 2013). In contrast, theta rhythms are associated with hippocampal-prefrontal interactions and sensorimotor integration (Buzsáki 2002). Therefore, the concurrent reduction in delta power and increase in theta activity observed here may reflect not only local activation of the STN but also broader reorganization of neural dynamics across interconnected arousal-related circuits. In this context, Redinbaugh et al. demonstrated that the central lateral thalamus and deep cortical layers are especially responsive to alterations in the level of consciousness across wakefulness, sleep, and anesthesia, and that thalamic control over deep-layer cortical activity plays a key role in the restoration of arousal (Redinbaugh et al. 2020). Related commentary further emphasized that central thalamic stimulation can reactivate the cortex by restoring deep-layer firing and modulating feedforward and feedback connectivity (Schiff 2020). Within this systems-level framework, the present findings suggest that the STN and its downstream VP projection may function as components of a broader arousal-promoting network that facilitates emergence from propofol anesthesia, potentially by promoting recovery of cortical dynamics supported by basal ganglia-thalamocortical and thalamocortical circuits. Although thalamic nuclei or cortical laminar networks were not directly recorded in this study, the pronounced EEG desynchronization and shortened RORR induced by activation of STN CaMKIIα-expressing neurons and STN–VP terminals are consistent with such a network-level interpretation. During anesthesia, STN CaMKIIα-expressing neurons likely promote arousal through their downstream projections. Consistent with earlier studies, anterograde tracing in the present work revealed that STN axons innervate multiple brain regions involved in sleep–wake regulation and general anesthesia, including the substantia nigra (Dong et al. 2022), VP (Xu et al. 2025), PBN (Jia et al. 2023), and pontine nuclei (Bhuvanasundaram et al. 2022). Among these targets, the VP is a key basal ganglia structure composed of GABAergic, cholinergic, and glutamatergic neurons (Morais-Silva and Lobo 2024) and plays central roles in control, learning, motivation, and arousal (Soares-Cunha and Heinsbroek 2023; Xu et al. 2025). Activation of either GABAergic or glutamatergic VP neurons suppresses NREM sleep, promotes wakefulness, and facilitates emergence in mice anesthetized with isoflurane or propofol (Xu et al. 2025; Zhou et al. 2024). Previous work has demonstrated that the VP receives dense afferent input from the ventromedial subdivision of the STN (Prasad and Wallén-Mackenzie 2024), a finding that was confirmed here using retrograde tracing. Notably, numerous glutamatergic marker‑labeled neurons have been identified in the ventromedial STN (Lévesque and Parent 2005), further supporting a prominent role for STN CaMKIIα-expressing neurons in regulating VP function. Moreover, optogenetic activation of STN CaMKIIα-expressing axon terminals in the VP induced cortical activation, robust behavioral arousal, and accelerated emergence from propofol anesthesia, supporting the VP as a downstream target through which the STN modulates arousal-related state transitions under propofol. Notably, the effects observed during optogenetic inhibition of the STN–VP pathway should not be interpreted as reflecting a purely direct synaptic mechanism. Although reduced STN-derived glutamatergic input to the VP is likely involved, indirect contributions from local VP microcircuits and broader basal ganglia-arousal network dynamics cannot be excluded. Future studies employing cell-type-specific manipulations and recordings within the VP will be required to further dissect the synaptic and circuit basis of this pathway-level effect. Beyond the functionally validated STN–VP pathway, viral tracing in the current study showed that the SNc is an additional downstream target of STN CaMKIIα-expressing neurons. Progressive degeneration of dopaminergic neurons in the SNc represents a hallmark pathological feature of Parkinson’s disease (Guatteo et al. 2022). Clinical studies further suggest that STN-DBS can improve certain sleep-related symptoms in patients with Parkinson’s disease (Amara et al. 2012; Zhu et al. 2023). In addition, previous reports indicate that SNc dopaminergic neurons participate in sleep–wake regulation and that dysfunction of this system may be associated with disturbances in sleep architecture (Qiu et al. 2019). Taken together, these observations imply that the STN–SNc pathway may represent a potential circuit substrate linking STN function to Parkinsonian sleep abnormalities and to sleep/anesthesia-related state transitions. However, because the present study did not directly evaluate the functional role of this pathway, this interpretation remains speculative. From a translational perspective, it is also important to note that the propofol regimen used in mice should not be interpreted as directly equivalent to a human anesthetic dose on a simple mg/kg basis. Cross-species extrapolation of propofol depends on body-size scaling, pharmacokinetics, and species-specific metabolism, all of which differ substantially between rodents and humans (Knibbe et al. 2005; Sahinovic et al. 2018). Therefore, the present dosing paradigm should be considered an experimental regimen designed to produce stable unconsciousness and emergence in mice for mechanistic investigation, rather than a direct clinical dose equivalent. Several limitations should be acknowledged. First, although the principal neuronal population of the STN is largely VGLUT2-positive and glutamatergic, CaMKIIα is not a fully specific molecular marker for all glutamatergic neurons in this region. Therefore, the manipulated population in the present study is more appropriately described as STN CaMKIIα-expressing neurons rather than the entire glutamatergic population, and a small degree of off-target manipulation cannot be entirely excluded. Second, although STN CaMKIIα-expressing neurons project to multiple downstream regions, only the STN–VP pathway was functionally investigated in this study. Third, the specific VP neuronal subtypes mediating STN-driven arousal remain unclear. Fourth, because RORR is a motor-dependent endpoint and the STN is a motor-associated nucleus, these findings are interpreted more cautiously as reflecting behavioral emergence and arousal-related state transitions rather than a direct one-to-one measure of conscious processing. Finally, additional physiological variables such as heart rate, respiratory rate, blood pressure, or pupillary responses were not simultaneously monitored. Therefore, the findings should be interpreted primarily as reflecting cortical arousal and emergence-related state transitions rather than a comprehensive evaluation of anesthetic depth. Conclusion In summary, STN CaMKIIα-expressing neurons are identified as important modulators of emergence from propofol anesthesia. The findings support a role for the STN–VP pathway, at least in part, as a downstream circuit contributing to arousal-related state transitions during propofol anesthesia (Fig. 9). These findings offer new mechanistic understanding of the basal ganglia in general anesthesia and may inform the development of targeted pharmacological or neuromodulatory approaches to improve anesthetic recovery and clinical safety.Fig. 9Schematic model of state-dependent activity changes in STN CaMKIIα-expressing neurons and the STN–VP pathway during propofol anesthesia Schematic model of state-dependent activity changes in STN CaMKIIα-expressing neurons and the STN–VP pathway during propofol anesthesia Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (DOCX 2159 KB)Supplementary file2 (XLSX 13 KB) Supplementary file1 (DOCX 2159 KB) Supplementary file2 (XLSX 13 KB)